Ignite Creation Date:
2024-05-06 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06232278
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-30
First Post:
2024-01-22
Brief Title:
Long-term Results of Percutaneous Left Atrial Closure at Brest University Hospital CLAPOT
Sponsor:
University Hospital Brest
Organization:
University Hospital Brest
Study Overview
Official Title:
Long-term Results of Percutaneous Left Atrial Closure at Brest University Hospital
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CLAPOT
Brief Summary:
Atrial Fibrillation represents an important risk of cardioembolic stroke In more than 90 of cases thrombus originate in the left atrial appendage Therefore guidelines recommend the anticoagulation of patients with atrial fibrillation and a significant cardioembolic risk predicted by the CHA2DS2VASc score
However serious bleeding complications may definitively contraindicate the use of anticoagulants
For those patients percutaneous Left Atrial Appendage Occlusion LAAO has became a recommended alternative to prevent the thrombus formation and reduce the risk of cardioembolic events
In the CHU of Brest more than 120 patients have been treated with LAAO for the last 8 years with two different occluder devices WATCHMAN Boston Scientifc and AMPLATZER Amulet Abbott Laboratories
This retrospective longitudinal observational study named CLAPOT CHU of Brest Left Atrial Appendage Percutaneous Occlusion Treatment aims to evaluate the long term results of this procedure for effectiveness and safety and to compare the results between the two devices Watchman and Amplatzer
However serious bleeding complications may definitively contraindicate the use of anticoagulants
For those patients percutaneous Left Atrial Appendage Occlusion LAAO has became a recommended alternative to prevent the thrombus formation and reduce the risk of cardioembolic events
In the CHU of Brest more than 120 patients have been treated with LAAO for the last 8 years with two different occluder devices WATCHMAN Boston Scientifc and AMPLATZER Amulet Abbott Laboratories
This retrospective longitudinal observational study named CLAPOT CHU of Brest Left Atrial Appendage Percutaneous Occlusion Treatment aims to evaluate the long term results of this procedure for effectiveness and safety and to compare the results between the two devices Watchman and Amplatzer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None